azintuxizumab vedotin (ABBV-838)
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 08, 2020
Managing myeloma during the coronavirus pandemic
(YouTube)
- "Ravi Vij, MD, MBA...discusses how the management of myeloma has changed in light of COVID-19, and what can be done to minimize the impact of the virus."
Interview • Video
January 24, 2020
First-in-Human Phase 1 Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients With Relapsed and Refractory Multiple Myeloma.
(PubMed, Clin Cancer Res)
- P1; "These results demonstrate that ABBV-838 is safe and well tolerated in patients with RR MM with a very limited efficacy."
Clinical • Journal • P1 data
1 to 2
Of
2
Go to page
1